Compare FHN & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FHN | CGEN |
|---|---|---|
| Founded | 1864 | 1993 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.3B | 191.1M |
| IPO Year | 1994 | 2001 |
| Metric | FHN | CGEN |
|---|---|---|
| Price | $24.46 | $2.48 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 19 | 2 |
| Target Price | ★ $26.24 | $5.00 |
| AVG Volume (30 Days) | ★ 3.7M | 300.0K |
| Earning Date | 04-15-2026 | 05-18-2026 |
| Dividend Yield | ★ 2.79% | N/A |
| EPS Growth | ★ 37.50 | N/A |
| EPS | ★ 1.07 | N/A |
| Revenue | ★ $3,419,000,000.00 | N/A |
| Revenue This Year | $7.57 | N/A |
| Revenue Next Year | $4.07 | $75.09 |
| P/E Ratio | $22.97 | ★ N/A |
| Revenue Growth | ★ 7.18 | N/A |
| 52 Week Low | $19.80 | $1.30 |
| 52 Week High | $26.56 | $3.24 |
| Indicator | FHN | CGEN |
|---|---|---|
| Relative Strength Index (RSI) | 45.03 | 46.09 |
| Support Level | $24.48 | $2.23 |
| Resistance Level | $24.92 | $2.54 |
| Average True Range (ATR) | 0.38 | 0.12 |
| MACD | 0.02 | -0.03 |
| Stochastic Oscillator | 63.56 | 4.04 |
First Horizon Corp is the parent company of First Tennessee Bank, a prominent regional bank with about 200 branches around Tennessee. The company's reportable segments are: Commercial, Consumer & Wealth, Wholesale, and Corporate. The majority of its revenue is generated from Commercial, Consumer & Wealth. The Commercial, Consumer & Wealth segment offers financial products and services, including traditional lending and deposit taking, to commercial and consumer clients in the southern USA and other selected markets. The Wholesale segment delivers industry-specific products and services, while the Corporate segment provides internal support functions like finance, risk, and audit.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.